NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00338-0086-01 | 00338-0086 | Doxorubicin Hydrochloride Liposome | Doxorubicin Hydrochloride Liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 15, 2019 | In Use | |
72237-0101-01 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
00054-0382-25 | 00054-0382 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Sep 16, 2013 | In Use | |
21922-0041-12 | 21922-0041 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov 6, 2023 | In Use | |
63323-0622-00 | 63323-0622 | PEMETREXED DISODIUM | Pemetrexed | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
51285-0369-01 | 51285-0369 | Methotrexate | Trexall | 15.0 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 3, 2001 | In Use | |
00093-7664-56 | 00093-7664 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | In Use | |
50742-0438-10 | 50742-0438 | arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 15, 2018 | In Use | |
54868-5260-02 | 54868-5260 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 28, 2005 | In Use | |
76189-0534-30 | 76189-0534 | Ponatinib Hydrochloride | Iclusig | 45.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
71288-0148-51 | 71288-0148 | Pemetrexed disodium | Pemetrexed | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec 13, 2022 | In Use | |
45963-0615-56 | 45963-0615 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jan 5, 2015 | In Use | |
67457-0215-01 | 67457-0215 | Melphalan Hydrochloride | Melphalan Hydrochloride | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 10, 2013 | Jan 31, 2026 | In Use |
50742-0492-01 | 50742-0492 | Carmustine | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Jun 25, 2022 | In Use | |||
68001-0643-06 | 68001-0643 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 1, 2025 | In Use | |
00310-0512-28 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Apr 1, 2018 | Jul 31, 2021 | In Use |
00085-1425-05 | 00085-1425 | Temozolomide | Temodar | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use | |
69539-0159-01 | 69539-0159 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
68001-0609-33 | 68001-0609 | Cisplatin | CISPLATIN | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 1, 2024 | In Use | |
59572-0102-01 | 59572-0102 | Azacitidine | Vidaza | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jul 5, 2004 | In Use | |
51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug 7, 2017 | Jan 31, 2024 | No Longer Used |
55390-0492-01 | 55390-0492 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Oct 22, 2001 | Jan 31, 2013 | No Longer Used | |
67457-0519-20 | 67457-0519 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Feb 28, 2018 | In Use | |
59651-0205-08 | 59651-0205 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 17, 2018 | In Use | |
00143-9098-01 | 00143-9098 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 27, 2022 | In Use |
Found 11465 results — Export these results